1. Home
  2. OCG vs AZTR Comparison

OCG vs AZTR Comparison

Compare OCG & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oriental Culture Holding LTD

OCG

Oriental Culture Holding LTD

HOLD

Current Price

$1.80

Market Cap

3.3M

ML Signal

HOLD

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.13

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OCG
AZTR
Founded
2018
2014
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
3.5M
IPO Year
2019
2023

Fundamental Metrics

Financial Performance
Metric
OCG
AZTR
Price
$1.80
$0.13
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
115.7K
622.6K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
8.57%
N/A
EPS Growth
N/A
5.06
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.01
$0.10
52 Week High
$19.29
$1.36

Technical Indicators

Market Signals
Indicator
OCG
AZTR
Relative Strength Index (RSI) 58.88 45.36
Support Level $1.62 $0.12
Resistance Level $1.83 $0.15
Average True Range (ATR) 0.10 0.01
MACD 0.01 0.00
Stochastic Oscillator 69.70 35.56

Price Performance

Historical Comparison
OCG
AZTR

About OCG Oriental Culture Holding LTD

Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. The company generates revenue through listing service fees, transaction fees, and other revenues collected from traders.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: